Passage BIO, Inc. (PASG) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-Q	10-Q
Revenues	1.6	0.3	-2.7				20.9	26.4
Cost of goods sold	0.0	0.0	0.0				56.9	56.9
Gross profit	1.6	0.3	-2.7				-35.9	-30.4
Gross margin	100.0%	100.0%	100.0%				-171.7%	-115.1%
Selling, general and administrative [+]	48.4	53.3	49.3				53.0	45.8
General and administrative	48.4	53.3	49.3				53.0	45.8
Research and development	67.2	76.7	86.1				84.7	78.9
Other operating expenses	3.1	1.8
EBITDA [+]	-113.2	-127.7	-134.7				-172.8	-154.5
EBITDA growth							98.9%	120.3%
EBITDA margin	-7178.8%	-40536.8%	4936.4%				-825.3%	-584.4%
Depreciation and amortization	3.8	3.8	3.7				0.9	0.7
EBIT [+]	-117.0	-131.5	-138.4				-173.6	-155.2
EBIT growth							98.6%	120.2%
EBIT margin	-7421.8%	-41734.9%	5071.2%				-829.5%	-587.0%
Interest income			2.0				0.4	0.4
Interest income			2.0				0.4	0.4
Other income (expense), net	3.1	1.8
Pre-tax income	-112.0	-127.7	-136.1				-173.2	-154.8
Income taxes	0.0	0.0	0.0				0.0	0.0
Tax rate	0.0%	0.0%	0.0%				0.0%	0.0%
Net income	-112.0	-127.7	-136.1				-173.2	-154.8
Net margin	-7099.9%	-40524.4%	4988.1%				-827.3%	-585.6%

Basic EPS [+]	($2.05)	($2.34)	($2.50)				($3.38)	($3.15)
Growth							10.3%	-18.6%
Diluted EPS [+]	($2.05)	($2.34)	($2.50)				($3.38)	($3.15)
Growth							10.3%	-18.6%

Shares outstanding (basic) [+]	54.6	54.5	54.4				51.2	49.1
Growth							81.6%	174.6%
Shares outstanding (diluted) [+]	54.6	54.5	54.4				51.2	49.1
Growth							81.6%	174.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.